Precise Minimally InvasiveTreatment of VT Using Non-invasive Mapping.

使用无创标测对 VT 进行精确的微创治疗。

• 批准号: 9348049
• 负责人: Dwight Meglan
• 金额: $ 54.79万
• 依托单位: HEARTLANDER SURGICAL, INC.
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-08-15 至 2019-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9348049
• 关键词: Ablation; Adoption; Adverse effects; Affect; Algorithms; Animals; Anti-Arrhythmia Agents; Area; Arrhythmia; Blood Vessels; Cardiac; Cessation of life; Chronic; Clinic; Complex; Distress; Doppler Ultrasound; Electrodes; Eligibility Determination; Failure; Family suidae; Film; Funding; Heart; Hour; Imagery; Implantable Defibrillators; Lesion; Life; Maps; Methodology; Modeling; Morphology; Myocardial; Myocardial Infarction; Myocardium; Navigation System; Needles; Operative Surgical Procedures; Pain; Pathway interactions; Patient-Focused Outcomes; Patients; Pattern; Pericardial body location; Pharmaceutical Preparations; Phase; Physiological; Population; Process; Public Health; Radiofrequency Interstitial Ablation; Recurrence; Risk; Safety; Saline; Shock; Signal Transduction; Site; Small Business Innovation Research Grant; System; Techniques; Technology; Testing; Therapeutic; Thinness; Tissues; Ultrasonography; United States; United States National Institutes of Health; Ventricular Tachycardia; Walkers; Work; base; commercialization; computer infrastructure; cost; design; experimental study; flexibility; hemodynamics; implantation; improved; in vivo; innovation; innovative technologies; miniaturize; minimally invasive; novel; reduce symptoms; sensor; sudden cardiac death; tool

Project Summary Ventricular Tachycardia (VT) is a major public health problem associated with the majority of the 300,000 cases of sudden cardiac death in the United States each year. The best current therapy for VT involves drugs to reduce VT episodes plus implantation of a cardiac defibrilator (ICD) that prolongs life by terminating episodes of VT. Permanent cessation of VT can be achieved by ablation of the origin site(s) and exit pathway(s) of the arrhythmia. Despite the advantages of this technique, its adoption has been limited because it is currently appropriate only for the few patients with hemodynamically stable VT. This project will create a disruptive, less expensive, more effective, and safer system for minimally invasive identification and ablation of critical VT sites. It will combine the HeartLander (HL) epicardial walker with a non-invasive mapping technology and a flexible, needle-based, radio frequency ablation technique. In prior work we have demonstrated that these technologies can be integrated into a unified system and have also eliminated major technical risks of the technologies. In this Fast Track SBIR application, we propose to complete the integration of the technologies and then verify the efficacy of the system in a Yorkshire swine pig model of VT. Upon successful completion, we will be ready to advance to the clinic a simpler, safer, more reliable and less expensive approach to effectively treating the 500,000 annual cases of ventricular tachycardia. We will also have built the hardware and computation infrastructure to support additional mapping methodologies that will enable the treatment of complex multi-focal arrhythmias.

项目摘要 心室心动过速（VT）是与大多数的主要公共卫生问题 美国每年有30万例心脏死亡。当前最好的治疗 VT涉及减少VT发作的药物以及心脏除纤维（ICD）的植入 通过终止VT的发作来延长寿命。可以通过消融实现永久停止VT 心律不齐的原点位点和出口途径。尽管有这种技术的优势， 它的采用受到限制，因为目前仅适用于少数患者 血液动力学稳定的VT。 该项目将创造一个颠覆性，更便宜，更有效和更安全的系统 关键VT站点的侵入性识别和消融。它将结合Heartlander（HL）心外膜 具有非侵入性映射技术的步行者和灵活的，基于针的射频消融 技术。在先前的工作中，我们证明了这些技术可以集成到 统一系统，还消除了技术的主要技术风险。 在这个快速的SBIR应用程序中，我们建议完成技术和 然后验证该系统在VT的约克郡猪猪模型中的功效。成功 完成，我们将准备前往诊所，更简单，更安全，更可靠，更少 昂贵的方法可以有效治疗500,000例年度心脏心动过速病例。我们 还将构建硬件和计算基础架构以支持其他映射 将能够治疗复杂的多焦心律失常的方法。